Cargando…

Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients

OBJECTIVE: Coronavirus disease 2019 (COVID-19) is a systemic disease induced by SARS-CoV-2 causing myocardial injury. To date, there are few data on the correlation between mid-regional proAdrenomedullin (MR-proADM) and myocardial injury. The aim of this study was to evaluate whether the association...

Descripción completa

Detalles Bibliográficos
Autores principales: Spoto, Silvia, Mangiacapra, Fabio, D’Avanzo, Giorgio, Lemme, Daniela, Bustos Guillén, César, Abbate, Antonio, Markley, John Daniel, Sambuco, Federica, Markley, Roshanak, Fogolari, Marta, Locorriere, Luciana, Lupoi, Domenica Marika, Battifoglia, Giulia, Costantino, Sebastiano, Ciccozzi, Massimo, Angeletti, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643355/
https://www.ncbi.nlm.nih.gov/pubmed/36388948
http://dx.doi.org/10.3389/fmed.2022.929408
_version_ 1784826506846928896
author Spoto, Silvia
Mangiacapra, Fabio
D’Avanzo, Giorgio
Lemme, Daniela
Bustos Guillén, César
Abbate, Antonio
Markley, John Daniel
Sambuco, Federica
Markley, Roshanak
Fogolari, Marta
Locorriere, Luciana
Lupoi, Domenica Marika
Battifoglia, Giulia
Costantino, Sebastiano
Ciccozzi, Massimo
Angeletti, Silvia
author_facet Spoto, Silvia
Mangiacapra, Fabio
D’Avanzo, Giorgio
Lemme, Daniela
Bustos Guillén, César
Abbate, Antonio
Markley, John Daniel
Sambuco, Federica
Markley, Roshanak
Fogolari, Marta
Locorriere, Luciana
Lupoi, Domenica Marika
Battifoglia, Giulia
Costantino, Sebastiano
Ciccozzi, Massimo
Angeletti, Silvia
author_sort Spoto, Silvia
collection PubMed
description OBJECTIVE: Coronavirus disease 2019 (COVID-19) is a systemic disease induced by SARS-CoV-2 causing myocardial injury. To date, there are few data on the correlation between mid-regional proAdrenomedullin (MR-proADM) and myocardial injury. The aim of this study was to evaluate whether the association of myocardial injury and elevated mid-regional proAdrenomedullin values could predict mortality of SARS-CoV-2 patients, to offer the best management to COVID-19 patients. MATERIALS AND METHODS: All patients hospitalized for SARS-CoV-2 infection at the COVID-19 Center of the Campus Bio-Medico of Rome University were included between October 2020 and March 2021 and were retrospectively analyzed. Myocardial injury was defined as rising and/or fall of cardiac hs Troponin I values with at least one value above the 99th percentile of the upper reference limit (≥15.6 ng/L in women and ≥34.2 ng/L in men). The primary outcome was 30-day mortality. Secondary outcomes were the comparison of MR-proADM, CRP, ferritin, and PCT as diagnostic and prognostic biomarkers of myocardial injury. Additionally, we analyzed the development of ARDS, the need for ICU transfer, and length of stay (LOS). RESULTS: A total of 161 patients were included in this study. Of these, 58 (36.0%) presented myocardial injury at admission. An MR-proADM value ≥ 1.19 nmol/L was defined as the optimal cut-off to identify patients with myocardial injury (sensitivity 81.0% and specificity 73.5%). A total of 121 patients (75.2%) developed ARDS, which was significantly more frequent among patients with myocardial injury (86.2 vs. 68.9%, p = 0.015). The overall 30-day mortality was 21%. Patients with myocardial injury presented significantly higher mortality compared to those without the same (46.6 vs. 6.8%, p < 0.001). When dividing the entire study population into four groups, based on the presence of myocardial injury and MR-proADM values, those patients with both myocardial injury and MR-proADM ≥ 1.19 nmol/L presented the highest mortality (53.2%, p < 0.001). The combination of myocardial injury and MR-proADM values ≥ 1.19 nmol/L was an independent predictor of death (OR = 7.82, 95% CI = 2.87–21.30; p < 0.001). CONCLUSION: The study is focused on the correlation between myocardial injury and MR-proADM. Myocardial injury induced by SARS-CoV-2 is strongly associated with high MR-proADM values and mortality.
format Online
Article
Text
id pubmed-9643355
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96433552022-11-15 Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients Spoto, Silvia Mangiacapra, Fabio D’Avanzo, Giorgio Lemme, Daniela Bustos Guillén, César Abbate, Antonio Markley, John Daniel Sambuco, Federica Markley, Roshanak Fogolari, Marta Locorriere, Luciana Lupoi, Domenica Marika Battifoglia, Giulia Costantino, Sebastiano Ciccozzi, Massimo Angeletti, Silvia Front Med (Lausanne) Medicine OBJECTIVE: Coronavirus disease 2019 (COVID-19) is a systemic disease induced by SARS-CoV-2 causing myocardial injury. To date, there are few data on the correlation between mid-regional proAdrenomedullin (MR-proADM) and myocardial injury. The aim of this study was to evaluate whether the association of myocardial injury and elevated mid-regional proAdrenomedullin values could predict mortality of SARS-CoV-2 patients, to offer the best management to COVID-19 patients. MATERIALS AND METHODS: All patients hospitalized for SARS-CoV-2 infection at the COVID-19 Center of the Campus Bio-Medico of Rome University were included between October 2020 and March 2021 and were retrospectively analyzed. Myocardial injury was defined as rising and/or fall of cardiac hs Troponin I values with at least one value above the 99th percentile of the upper reference limit (≥15.6 ng/L in women and ≥34.2 ng/L in men). The primary outcome was 30-day mortality. Secondary outcomes were the comparison of MR-proADM, CRP, ferritin, and PCT as diagnostic and prognostic biomarkers of myocardial injury. Additionally, we analyzed the development of ARDS, the need for ICU transfer, and length of stay (LOS). RESULTS: A total of 161 patients were included in this study. Of these, 58 (36.0%) presented myocardial injury at admission. An MR-proADM value ≥ 1.19 nmol/L was defined as the optimal cut-off to identify patients with myocardial injury (sensitivity 81.0% and specificity 73.5%). A total of 121 patients (75.2%) developed ARDS, which was significantly more frequent among patients with myocardial injury (86.2 vs. 68.9%, p = 0.015). The overall 30-day mortality was 21%. Patients with myocardial injury presented significantly higher mortality compared to those without the same (46.6 vs. 6.8%, p < 0.001). When dividing the entire study population into four groups, based on the presence of myocardial injury and MR-proADM values, those patients with both myocardial injury and MR-proADM ≥ 1.19 nmol/L presented the highest mortality (53.2%, p < 0.001). The combination of myocardial injury and MR-proADM values ≥ 1.19 nmol/L was an independent predictor of death (OR = 7.82, 95% CI = 2.87–21.30; p < 0.001). CONCLUSION: The study is focused on the correlation between myocardial injury and MR-proADM. Myocardial injury induced by SARS-CoV-2 is strongly associated with high MR-proADM values and mortality. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9643355/ /pubmed/36388948 http://dx.doi.org/10.3389/fmed.2022.929408 Text en Copyright © 2022 Spoto, Mangiacapra, D’Avanzo, Lemme, Bustos Guillén, Abbate, Markley, Sambuco, Markley, Fogolari, Locorriere, Lupoi, Battifoglia, Costantino, Ciccozzi and Angeletti. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Spoto, Silvia
Mangiacapra, Fabio
D’Avanzo, Giorgio
Lemme, Daniela
Bustos Guillén, César
Abbate, Antonio
Markley, John Daniel
Sambuco, Federica
Markley, Roshanak
Fogolari, Marta
Locorriere, Luciana
Lupoi, Domenica Marika
Battifoglia, Giulia
Costantino, Sebastiano
Ciccozzi, Massimo
Angeletti, Silvia
Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients
title Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients
title_full Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients
title_fullStr Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients
title_full_unstemmed Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients
title_short Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients
title_sort synergistic effect of myocardial injury and mid-regional proadrenomedullin elevation in determining clinical outcomes of sars-cov-2 patients
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643355/
https://www.ncbi.nlm.nih.gov/pubmed/36388948
http://dx.doi.org/10.3389/fmed.2022.929408
work_keys_str_mv AT spotosilvia synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT mangiacaprafabio synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT davanzogiorgio synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT lemmedaniela synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT bustosguillencesar synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT abbateantonio synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT markleyjohndaniel synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT sambucofederica synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT markleyroshanak synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT fogolarimarta synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT locorriereluciana synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT lupoidomenicamarika synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT battifogliagiulia synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT costantinosebastiano synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT ciccozzimassimo synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients
AT angelettisilvia synergisticeffectofmyocardialinjuryandmidregionalproadrenomedullinelevationindeterminingclinicaloutcomesofsarscov2patients